CA1314220C - Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure - Google Patents
Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressureInfo
- Publication number
- CA1314220C CA1314220C CA000562902A CA562902A CA1314220C CA 1314220 C CA1314220 C CA 1314220C CA 000562902 A CA000562902 A CA 000562902A CA 562902 A CA562902 A CA 562902A CA 1314220 C CA1314220 C CA 1314220C
- Authority
- CA
- Canada
- Prior art keywords
- prostaglandin
- composition
- pgf2
- mixture
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000003180 prostaglandins Chemical class 0.000 title claims abstract description 61
- 230000004410 intraocular pressure Effects 0.000 title claims abstract description 41
- 239000000674 adrenergic antagonist Substances 0.000 title claims abstract description 33
- 230000009467 reduction Effects 0.000 title abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 59
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 21
- 206010030043 Ocular hypertension Diseases 0.000 claims abstract description 17
- 230000001603 reducing effect Effects 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 230000000699 topical effect Effects 0.000 claims abstract description 10
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical group CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 claims description 34
- -1 -isopropyl ester Chemical class 0.000 claims description 19
- 239000002876 beta blocker Substances 0.000 claims description 18
- 229940097320 beta blocking agent Drugs 0.000 claims description 17
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical group O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 16
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical group [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims description 14
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical group OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 claims description 13
- 229960004834 levobunolol hydrochloride Drugs 0.000 claims description 13
- 229960005221 timolol maleate Drugs 0.000 claims description 12
- 150000002148 esters Chemical class 0.000 claims description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 229960004347 betaxolol hydrochloride Drugs 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- PXGPLTODNUVGFL-YNNPMVKQSA-N prostaglandin F2alpha Chemical group CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-YNNPMVKQSA-N 0.000 claims 9
- 238000000034 method Methods 0.000 abstract description 10
- 241000282326 Felis catus Species 0.000 description 15
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 13
- 210000003205 muscle Anatomy 0.000 description 13
- 229960004605 timolol Drugs 0.000 description 13
- 230000001886 ciliary effect Effects 0.000 description 12
- 230000001077 hypotensive effect Effects 0.000 description 12
- 210000001742 aqueous humor Anatomy 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000001747 pupil Anatomy 0.000 description 7
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 6
- 229960001416 pilocarpine Drugs 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 241000288906 Primates Species 0.000 description 4
- 229940072329 betoptic Drugs 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960000831 levobunolol Drugs 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 210000002159 anterior chamber Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 150000003943 catecholamines Chemical class 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000001585 trabecular meshwork Anatomy 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 229940098085 betagan Drugs 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- DNTDOBSIBZKFCP-YDALLXLXSA-N levobunolol hydrochloride Chemical compound [Cl-].O=C1CCCC2=C1C=CC=C2OC[C@@H](O)C[NH2+]C(C)(C)C DNTDOBSIBZKFCP-YDALLXLXSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010052127 Anterior chamber flare Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000893710 Homo sapiens Galactoside alpha-(1,2)-fucosyltransferase 2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001710 bronchial artery Anatomy 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940034744 timoptic Drugs 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3448487A | 1987-04-03 | 1987-04-03 | |
| US034,484 | 1987-04-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1314220C true CA1314220C (en) | 1993-03-09 |
Family
ID=21876714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000562902A Expired - Lifetime CA1314220C (en) | 1987-04-03 | 1988-03-30 | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0286903B2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2726672B2 (cg-RX-API-DMAC7.html) |
| AT (1) | ATE76750T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU607981B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA1314220C (cg-RX-API-DMAC7.html) |
| DE (1) | DE3871596T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2042625T5 (cg-RX-API-DMAC7.html) |
| GR (2) | GR3004794T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HU211835A9 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1334168C (en) * | 1988-04-26 | 1995-01-31 | Louis M. De Santis | Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers |
| US5173507A (en) * | 1988-07-18 | 1992-12-22 | Alcon Laboratories, Inc. | Prostaglandin combinations in glaucoma therapy |
| CA2021316C (en) * | 1989-07-27 | 2000-10-24 | Ming Fai Chan | Intraocular pressure reducing 11-acyl prostaglandins |
| US5028624A (en) * | 1989-07-27 | 1991-07-02 | Allergan, Inc. | Intraocular pressure reducing 9,15-diacyl prostaglandins |
| US4994274A (en) * | 1989-07-27 | 1991-02-19 | Allergan, Inc. | Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using |
| US5055467A (en) * | 1989-11-13 | 1991-10-08 | Allergan, Inc. | Pharmaceutical epinephrine-pilocarpine compounds |
| US5198545A (en) * | 1989-11-13 | 1993-03-30 | Allergan, Inc. | Pharmaceutical epinephrine-pilocarpine compounds and process of preparation thereof |
| US5011856A (en) * | 1990-03-12 | 1991-04-30 | Allergan, Inc. | Use of prostaglandin F3 α as an ocular hypotensive agent |
| ES2059058T3 (es) * | 1990-05-22 | 1994-11-01 | R Tech Ueno Ltd | Combinacion sinergica para uso oftalmico. |
| EP0458590B1 (en) * | 1990-05-22 | 1996-01-10 | R-Tech Ueno Ltd. | Treatment of ocular hypertention with a synergistic combination |
| ES2069823T3 (es) * | 1990-05-22 | 1995-05-16 | R Tech Ueno Ltd | Tratamiento de la hipertension ocular con una combinacion sinergica ocular. |
| US5238961A (en) * | 1990-06-14 | 1993-08-24 | Allergan, Inc. | Pgf 1-alcohols and their use as ocular hypotensives |
| TW210287B (cg-RX-API-DMAC7.html) * | 1991-03-01 | 1993-08-01 | Kabushikaisha Ueno Seiyaku Oyo Kenkyujo | |
| PT561073E (pt) * | 1992-03-19 | 2002-04-29 | R Tech Ueno Ltd | Tratamento da hipertensao ocular com beta-bloqueadores e derivados de acido prostanoico |
| JPH06107547A (ja) * | 1992-10-01 | 1994-04-19 | Aarutetsuku Ueno:Kk | 眼科用組成物 |
| ES2105333T3 (es) * | 1992-10-13 | 1997-10-16 | Alcon Lab Inc | Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma. |
| US5574066A (en) * | 1992-10-28 | 1996-11-12 | Allergan | Intraocular pressure reducing 15-acyl prostaglandins |
| SE9402816D0 (sv) * | 1994-08-24 | 1994-08-24 | Pharmacia Ab | Method and meams for drug administration |
| US5698733A (en) * | 1994-09-30 | 1997-12-16 | Alcon Laboratories, Inc. | Use of 9-deoxy prostaglandin derivatives to treat glaucoma |
| AU746893B2 (en) * | 1998-01-23 | 2002-05-02 | Merck Sharp & Dohme B.V. | Method for increasing oxygen tension in the optic nerve and retina |
| CN1259051C (zh) * | 2001-04-19 | 2006-06-14 | 帝化制药株式会社 | 药物及药物试剂盒 |
| TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
| AU2007200821A1 (en) * | 2001-05-31 | 2007-03-15 | Allergan, Inc. | Hypotensive lipid and timolol compositions and methods of using same |
| TW200305424A (en) | 2002-01-29 | 2003-11-01 | Santen Pharmaceutical Co Ltd | Glaucoma-treating agent comprising bunazosin and prostaglandin |
| EP1541151B1 (en) * | 2002-08-29 | 2012-02-22 | Santen Pharmaceutical Co., Ltd. | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS |
| KR101223886B1 (ko) * | 2002-11-18 | 2013-01-17 | 산텐 세이야꾸 가부시키가이샤 | Ｒｈｏ 키나아제 억제제와 β 차단약으로 이루어진 녹내장 치료제 |
| US7186744B2 (en) * | 2003-11-13 | 2007-03-06 | Allergan, Inc. | Prostamides for the treatment of glaucoma and related diseases |
| ES2416334T3 (es) | 2005-07-12 | 2013-07-31 | Kowa Company. Ltd. | Agente para la prevención o el tratamiento del glaucoma |
| EP2127638A1 (en) * | 2008-05-30 | 2009-12-02 | Santen Pharmaceutical Co., Ltd | Method and composition for treating ocular hypertension and glaucoma |
| WO2011034192A1 (ja) * | 2009-09-17 | 2011-03-24 | 千寿製薬株式会社 | ラタノプロストを含有する水性点眼剤、並びにラタノプロストの樹脂への吸着の抑制方法 |
| EP2598118B1 (en) | 2010-07-29 | 2018-09-05 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
| EP2671586B1 (en) | 2011-02-04 | 2018-05-30 | Kowa Co., Ltd. | Drug therapy for preventing or treating glaucoma |
| CA3099517C (en) * | 2012-07-13 | 2022-04-26 | Santen Pharmaceutical Co., Ltd. | Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension |
| WO2018033854A1 (en) | 2016-08-15 | 2018-02-22 | Santen Pharmaceutical Co., Ltd. | Ophthalmic composition and a method for treating ocular hypertension and glaucoma |
| KR20200103041A (ko) | 2017-12-21 | 2020-09-01 | 산텐 세이야꾸 가부시키가이샤 | 오미데네팍의 조합 |
| ES2972934T3 (es) | 2017-12-21 | 2024-06-17 | Santen Pharmaceutical Co Ltd | Combinación de sepetaprost y ripasudil para su uso en la profilaxis o tratamiento del glaucoma o hipertensión ocular |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4454154A (en) * | 1981-06-23 | 1984-06-12 | American Hospital Supply Corporation | Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents |
| US4599353A (en) * | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
| DE3300933A1 (de) * | 1983-01-13 | 1984-07-19 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten |
| DE3785602T2 (de) * | 1986-03-13 | 1993-09-02 | Univ Columbia | Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom. |
-
1988
- 1988-03-28 ES ES88104999T patent/ES2042625T5/es not_active Expired - Lifetime
- 1988-03-28 AT AT88104999T patent/ATE76750T1/de not_active IP Right Cessation
- 1988-03-28 DE DE3871596T patent/DE3871596T3/de not_active Expired - Lifetime
- 1988-03-28 EP EP88104999A patent/EP0286903B2/en not_active Expired - Lifetime
- 1988-03-30 AU AU13870/88A patent/AU607981B2/en not_active Expired
- 1988-03-30 CA CA000562902A patent/CA1314220C/en not_active Expired - Lifetime
- 1988-04-01 JP JP63081167A patent/JP2726672B2/ja not_active Expired - Lifetime
-
1992
- 1992-06-04 GR GR920401036T patent/GR3004794T3/el unknown
-
1995
- 1995-06-28 HU HU95P/P00519P patent/HU211835A9/hu unknown
-
2000
- 2000-06-16 GR GR20000401411T patent/GR3033721T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| GR3004794T3 (cg-RX-API-DMAC7.html) | 1993-04-28 |
| HU211835A9 (en) | 1995-12-28 |
| DE3871596T3 (de) | 2000-09-07 |
| JP2726672B2 (ja) | 1998-03-11 |
| JPS63313728A (ja) | 1988-12-21 |
| ATE76750T1 (de) | 1992-06-15 |
| AU607981B2 (en) | 1991-03-21 |
| DE3871596T2 (de) | 1993-01-21 |
| EP0286903B2 (en) | 2000-03-29 |
| DE3871596D1 (de) | 1992-07-09 |
| EP0286903A1 (en) | 1988-10-19 |
| GR3033721T3 (en) | 2000-10-31 |
| ES2042625T3 (es) | 1993-12-16 |
| ES2042625T5 (es) | 2000-07-16 |
| AU1387088A (en) | 1988-10-06 |
| EP0286903B1 (en) | 1992-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1314220C (en) | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure | |
| US4952581A (en) | Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure | |
| EP0569046B1 (en) | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension | |
| KR100452715B1 (ko) | 녹내장및안구국소빈혈을치료하기위한특정이소퀴놀린술포닐화합물의용도 | |
| EP1392319B1 (en) | Hypotensive lipid (prostaglandin) and timolol compositions and methods of using same | |
| US6037368A (en) | 8-iso- prostaglandins for glaucoma therapy | |
| US4883819A (en) | Use of A, B and C prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma | |
| JPH10507743A (ja) | 薬剤投与のための方法と手段 | |
| EP2598118B1 (en) | Preservative free bimatoprost and timolol solutions | |
| US20060111388A1 (en) | Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye | |
| AU609807B2 (en) | A composition for the topical treatment of glaucoma or ocular hypertension | |
| EP0979652B1 (en) | Remedial composition for intraocular hypertension or glaucoma | |
| EP0366765B1 (en) | Antiglaucoma compositions containing combinations of sympathomimetic agents and beta-1 selective beta-blockers | |
| Podos et al. | Pharmacologic alteration of aqueous humor dynamics in normotensive and glaucomatous monkey eyes | |
| Podos et al. | Experimental compounds to lower intraocular pressure | |
| HK40003602A (en) | Preservative free bimatoprost and timolol solutions | |
| SHARIR et al. | A comparison of the efficacy of various metipranolol-pilocarpine combinations in patients with ocular hypertension and primary open-angle glaucoma | |
| HK1070830B (en) | Hypotensive lipid and timolol compositions and methods of using same | |
| HK1183793B (en) | Preservative free bimatoprost and timolol solutions | |
| HK1183793A (en) | Preservative free bimatoprost and timolol solutions | |
| AU2007200821A1 (en) | Hypotensive lipid and timolol compositions and methods of using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |